Neumora Therapeutics (NMRA) Q3 2024 earnings summary

Executive summary

• Advanced seven clinical and preclinical neuroscience programs targeting neuropsychiatric and neurodegenerative diseases, including major depressive disorder (MDD), bipolar disorder, Alzheimer's agitation, schizophrenia, Parkinson's, and ALS.

• Lead asset navacaprant is in three Phase 3 trials (KOASTAL-1, -2, -3) for MDD, with KOASTAL-1 topline data expected by year-end 2024 and KOASTAL-2 and -3 in the first half of 2025; also in Phase 2 for bipolar depression.

• Additional programs include NMRA-511 for Alzheimer's agitation and a muscarinic M4 franchise, with new clinical entries and IND submission for a second M4 PAM expected in 2025.

• No products approved or revenue from product sales; significant net losses since inception, driven by R&D and acquired in-process R&D costs.

• IPO completed in September 2023, raising $226.5 million; $341.3 million in cash, cash equivalents, and marketable securities as of September 30, 2024, expected to fund operations into mid-2026.

Financial highlights

• Total operating expenses for Q3 2024 were $76.6 million, up from $56.9 million in Q3 2023, primarily due to increased R&D activity for navacaprant and portfolio growth.

• Net loss of $72.5 million for Q3 2024, compared to $53.0 million in Q3 2023; net loss per share was $0.45 (basic and diluted) for Q3 2024.

• Research and development expenses rose 46% year-over-year to $60.6 million in Q3 2024; general and administrative expenses were $16.0 million.

• Interest income increased to $4.2 million in Q3 2024, reflecting higher cash balances.

• Cash, cash equivalents, and marketable securities totaled $341.3 million at quarter-end.

Outlook and guidance

• Five clinical catalysts anticipated over the next 18 months, including three Phase 3 readouts for navacaprant in MDD, data for navacaprant in bipolar depression, and NMRA-511 in Alzheimer's agitation.

• IND for a second M4 positive allosteric modulator expected in the first half of 2025.

• Cash runway projected to support operations into mid-2026.